Clear All
757 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
HCPCS Generic Name Brand Name Strength SEER*Rx Category Major Drug Class Minor Drug Class Oral (Y/N) FDA Approval Year FDA Discontinuation Year CMS Effective Date CMS Discontinuation Date Status
C9174 Datopotamab Deruxtecan Datroway 1mg Immunotherapy Drug Antibody Conjugate Topoisomerase I No 2025 Jul 9, 2025 In Use
J1323 Elranatamab-bcmm Elranatamab-bcmm 1mg Immunotherapy Monoclonal Antibody BCMA, CD3 No 2023 Apr 17, 2024 In Use
J7684 Triamcinolone Kenalog Aristocort 1 mg Hormonal Therapy Adrenal Glucocorticoid Corticosteroid No 1960 Jan 1, 2000 In Use
NA Chlorotrianisene Anisene 12 mg Hormonal Therapy Estrogen Yes 1992 1997 In Use
J9071 Cyclophosphamide (AuroMedics) Cyclophosphamide 5mg Chemotherapy Alkylating Agent Nitrogen mustard No 2021 Mar 25, 2022 In Use
Q5148 Filgrastim-txid (nypozi) Nypozi 1 microgram Ancillary Therapy Immunostimulant Colony-Stimulating Factor No 2024 Mar 26, 2025 In Use
Q0162 Ondansetron with active chemotherapy treatment adminstration Zofran, Zofran ODT, Zuplenz 1 mg Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Yes 1991 Jan 1, 2012 In Use
S0187 Tamoxifen Citrate Nolvadex, Nolvadex-D, Soltamox 10 mg Hormonal Therapy Selective Estrogen Receptor Modulator (SERM) Yes 1977 Jan 1, 2002 In Use
NA Trametinib Mekinist 0.5 mg Chemotherapy MEK Inhibitor BRAF Yes 2013 In Use
NA Pirtobrutinib Jaypirca Multiple Chemotherapy Tyrosine Kinase Inhibitor BTK Yes 2023 In Use
NA Aprepitant Emend 80 mg Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Yes 2003 In Use
J9352 Trabectedin Yondelis 0.1mg Chemotherapy Alkylating Agent Natural Product No 2015 Jan 1, 2017 In Use
J9206 Irinotecan Camptosar 20 mg Chemotherapy Topoisomerase I Inhibitor Campothecin Analogs No 1996 Jan 1, 1998 In Use
J1932 Lanreotide (Cipla) Lanreotide Acetate 1mg Hormonal Therapy Somatostatin Analog No 2021 Sep 27, 2022 In Use
J9298 Nivolumab & Relatlimab-rmbw Opdualag 3mg/1mg Immunotherapy Checkpoint Inhibitor, Monoclonal Antibody PD-1, LAG3 No 2022 Sep 27, 2022 In Use
J9310 Rituximab Rituxan 100 mg Immunotherapy Monoclonal Antibody CD20 No 1997 Jan 1, 1999 In Use
NA Erlotinib Tarceva 100 mg Chemotherapy Tyrosine Kinase Inhibitor EGFR Yes 2004 In Use
J1380 Estradiol Valerate Delestrogen 10 mg Hormonal Therapy Estrogen No 1954 Jan 1, 1997 In Use
NA Imiquimod Aldara 5% Immunotherapy Immunomodulator Retinoic Acid Derivative No 1997 In Use
J9072 Cyclophosphamide (avyxa) Cyclophosphamide avyxa 5mg Chemotherapy Alkylating Agent Nitrogen Mustard No 2023 Dec 7, 2023 In Use
NA Avapritinib Ayvakit 50mg Chemotherapy Tyrosine Kinase Inhibitor PDGFR, KIT, CSFR1 Yes 2020 In Use
NA Erlotinib Tarceva 25 mg Chemotherapy Tyrosine Kinase Inhibitor EGFR Yes 2004 In Use
J3121 Testosterone Enanthate Testosterone Enanthate 1 mg Hormonal Therapy Androgen No 1953 Jan 1, 2015 In Use
J9181 Etoposide Toposar, Etopophos 10 mg Chemotherapy Plant Alkaloid Epipodophyllotoxins No 1983 Jan 1, 1987 In Use
NA Abemaciclib Verzenio 50 mg Chemotherapy Cyclin Dependent Kinase Inhibitor CDK 4/6 Yes 2017 In Use
The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is truly not available.